A prescription medication indicated for the treatment of hypertension is being recalled.

The recall of a prescription blood thinner used to prevent stroke, heart attack, and other heart problems has been expanded to include two additional lots. 

Numerous valsartan recalls from a range of drugmakers have occurred this year due to probable cancer-causing impurities found in the prescription blood pressure medication and now Teva Pharmaceuticals is part of the list.

The FDA has issued a Class II recall for numerous lots of valsartan drug products due to the presence of the carcinogenic substance N-nitrosodiethylamine in an active pharmaceutical ingredient used to manufacture the drug.

Employers aiming to shift high drug costs to employees through prescription plans with multiple drug tiers do themselves and their workers a disservice, suggested a column published online in Health Affairs.

Treatment with a psoriasis drug may be associated with noninfectious pneumonia, according to a report by the FDA.

The international Fast-Track strategy to end the HIV/AIDS epidemic worldwide by 2030 makes solid financial sense, according to a study published online in Health Policy.

“The use of fixed-dose and free combination triple therapy in patient populations outside of those recommended in guidelines may unnecessarily increase the risks and costs of COPD treatment,” researchers wrote. 

Biogen Inc's Spinraza treatment for spinal muscular atrophy and Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its US price and long-term success rates, ICER recently reported. 

The FDA is warning that fluoroquinolone antibiotics can increase the occurrence of ruptures or tears in the aorta.